ITCI - Intra-Cellular Therapies Inc Stock Price, Fair Value and News

$85.59+0.14 (+0.16%)

Delayed as of 22 Nov 2024, 01:03 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ITCI Price Action

Last 7 days

-2.5%

Last 30 days

10.8%

Last 90 days

14.7%

Trailing 12 Months

44.2%

ITCI RSI Chart

ITCI Valuation

Market Cap

9.1B

Price/Earnings (Trailing)

-104.89

Price/Sales (Trailing)

14.76

EV/EBITDA

-101.6

Price/Free Cashflow

-128.74

ITCI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ITCI Fundamentals

ITCI Revenue

Revenue (TTM)

613.7M

Rev. Growth (Yr)

39%

Rev. Growth (Qtr)

8.67%

ITCI Earnings

Earnings (TTM)

-86.4M

Earnings Growth (Yr)

-8.52%

Earnings Growth (Qtr)

-62.29%

ITCI Profitability

EBT Margin

-13.87%

Return on Equity

-7.54%

Return on Assets

-6.52%

Free Cashflow Yield

-0.78%

ITCI Investor Care

Shares Dilution (1Y)

10.16%

Diluted EPS (TTM)

-0.87

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	513.9M	564.5M	613.7M	0
2023	310.6M	365.8M	420.1M	464.4M
2022	102.9M	138.5M	188.1M	250.3M
2021	37.6M	55.7M	70.6M	83.8M
2020	9.3M	13.8M	18.3M	22.8M
2019	0	0	0	4.8M
2017	426.0K	312.3K	338.7K	245.8K
2016	0	316.5K	263.5K	361.4K
2015	0	466.9K	247.7K	153.9K
2014	2.3M	1.9M	1.3M	577.3K
2013	3.1M	2.3M	2.6M	2.7M
2012	0	16.6M	9.9M	3.1M
2011	0	0	0	23.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

CEO	Dr. Sharon Mates Ph.D.
WEBSITE	intracellulartherapies.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	561

Intra-Cellular Therapies Inc Frequently Asked Questions

What is the ticker symbol for Intra-Cellular Therapies Inc? What does ITCI stand for in stocks?

ITCI is the stock ticker symbol of Intra-Cellular Therapies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intra-Cellular Therapies Inc (ITCI)?

As of Thu Nov 21 2024, market cap of Intra-Cellular Therapies Inc is 9.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ITCI stock?

You can check ITCI's fair value in chart for subscribers.

Is Intra-Cellular Therapies Inc a good stock to buy?

The fair value guage provides a quick view whether ITCI is over valued or under valued. Whether Intra-Cellular Therapies Inc is cheap or expensive depends on the assumptions which impact Intra-Cellular Therapies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ITCI.

What is Intra-Cellular Therapies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Nov 21 2024, ITCI's PE ratio (Price to Earnings) is -104.89 and Price to Sales (PS) ratio is 14.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ITCI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Intra-Cellular Therapies Inc's stock?

In the past 10 years, Intra-Cellular Therapies Inc has provided 0.189 (multiply by 100 for percentage) rate of return.